Abstract:Background: Bmi1 (B lymphoma Mo-MLV insertion region 1 homolog) contributes to human tumorigenesis via epigenetic transcriptional silencing and represents a novel therapeutic target with great potentials. Here we sought to determine the therapeutic efficiency of PTC-209, a potent and selective Bmi1 inhibitor, in head neck squamous cell carcinoma (HNSCC) cells and a HNSCC xenograft model. Methods: The mutation pattern, mRNA level of Bmi1 in HNSCC and its associations with clinicopathological parameters were determined through comprehensive data mining and interrogation using publicly available databases GENT, cBioPortal, Oncomine and TCGA. The PTC-209, a selective and potent Bmi1 inhibitor, was exploited and its effect on Bmi1 expression was measured in two HNSCC cell lines Cal27 and FaDu. The phenotypical changes of HNSCC cells were observed upon PTC-209 treatment in vitro. Moreover, the therapeutic effects of PTC-209 for HNSCC were determined in a xenograft animal model. Results: Through comprehensive data mining and interrogation, we found that Bmi1 mRNA was frequently over-expressed in a subset of HNSCC samples. Our data revealed that PTC-209 robustly reduced the expression of Bmi1 in Cal27 and FaDu cells presumably by post-transcriptional repression and ubiquitin-proteasomal degradation. PTC-209 treatment resulted in impaired cell proliferation, G1-phase cell cycle arrest, compromised migration and invasiveness, and increased cell apoptosis and chemosensitivity to 5-FU and cisplatin in vitro. Moreover, PTC-209 exposure reduced colony formation, tumorsphere formation and the percentage of ALDH1(+) subpopulation in both Cal27 and FaDu cells. Importantly, in vivo PTC-209 administration significantly reduced tumor growth in a HNSCC xenograft model probably by Bmi1 inhibition and impaired cell proliferation. Conclusions: Our findings indicate that pharmacological inhibition of Bmi1 is a novel therapeutic strategy for HNSCC patients, especially with those with aberrant Bmi1 overexpression.

Validation of Bmi1 As a Therapeutic Target of Hepatocellular Carcinoma in Mice.

Bmi1 Knockdown Inhibits Hepatocarcinogenesis.

MiR-148b Suppresses Cell Proliferation and Invasion in Hepatocellular Carcinoma by Targeting WNT1/β-catenin Pathway

Overexpression of Bmi-1 Contributes to the Invasion and Metastasis of Hepatocellular Carcinoma by Increasing the Expression of Matrix Metalloproteinase (MMP)-2, MMP-9 and Vascular Endothelial Growth Factor Via the PTEN/PI3K/Akt Pathway

Bmi1 Drives Hepatocarcinogenesis by Repressing the TGFβ2/SMAD Signalling Axis

Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil.

Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma

Bmi1 drives the formation and development of intrahepatic cholangiocarcinoma independent of Ink4A/Arf repression

Increased Polycomb-Group Oncogene Bmi-1 Expression Correlates with Poor Prognosis in Hepatocellular Carcinoma

Silencing Bmi-1 Expression by RNA Interference Suppresses the Growth of Laryngeal Carcinoma Cells.

Pharmacological Inhibition of Bmi1 by PTC-209 Impaired Tumor Growth in Head Neck Squamous Cell Carcinoma

Bmi-1 Promotes the Chemoresistance, Invasion and Tumorigenesis of Pancreatic Cancer Cells

Knockdown of BMI-1 Causes Cell-Cycle Arrest and Derepresses P16ink4a, HOXA9 and HOXC13 Mrna Expression in HeLa Cells

Bmi-1 Is Related To Proliferation, Survival And Poor Prognosis In Pancreatic Cancer

Expression and significance of the Bmi-1 gene in hepatocellular carcinoma

BMI-1, a promising therapeutic target for human cancer.

Bmi1 facilitates the progression of cholangiocarcinoma by inhibiting Foxn2 expression dependent on a histone H2A ubiquitination manner

The Crucial Roles of Bmi-1 in Cancer: Implications in Pathogenesis, Metastasis, Drug Resistance, and Targeted Therapies

Targeting Bmi1 for Enhancing Anoikis Sensitivity and Inhibiting Metastasis in Colorectal Cancer

Dkk1 Inhibits Malignant Transformation Induced by Bmi1 Via the Β‐catenin Signaling Axis in WB‐F344 Oval Cells

Elevated Expression of Bmi1 in Hepatocellular Carcinoma with Bile Duct Tumor Thrombi.